ВАКЦИНАЦІЯ ВІД СОVID-19: ОЧІКУВАННЯ, РЕАЛІЇ І ПЕРСПЕКТИВИ
DOI:
https://doi.org/10.11603/1681-2727.2021.1.11951Ключові слова:
COVID-19, вакцини, ефективність, побічні реакціїАнотація
На підставі огляду наукової літератури висвітлено сучасні підходи до створення вакцин-кандидатів проти COVID-19. Наведено дані про безпеку, ефективність, режими введення, небажані побічні ефекти, умови зберігання генетичних вакцин Тозінамеран, або BNT162b2, під торговою маркою Comirnaty (Pfizer-BioNTech), на матричній РНК (мРНК) і «Модерна» на основі мРНК-1273. Висвітлено дані доклінічних досліджень перспективної ДНК-плазмідної вакцини-кандидата ZyCoV-D. Охарактеризовано вірусні векторні вакцини: ChAdOx1 nCoV-19 (AZD1222), відома як вакцина AstraZeneca, а також Ad26.COV2.S (JNJ-78436735, VAC31518), в якій використовують генетично модифікований аденовірус ad26. Наведено обнадійливі попередні результати випробовувань субодиничної вакцини-кандидата NVX-CoV2373. Дано характеристику інактивованих вакцин BBIBP-CorV (Китай, Sinopharm) і CoronaVac (Sinovac Life Sciences, Пекін, Китай). Висвітлено питання доцільності вакцинації реконвалесцентів COVID-19, вагітних, дітей. Порушено проблему ефективності вакцин проти нових мутантних вірусів SARS-CoV-2.
Посилання
Shereen, M.A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91-98.
Coronavirus in the world as of Friday February 19, 2021: latest case and death tolls in 24h per country. (2020). https://www.sortiraparis.com. Retrieved from: https://www.sortiraparis.com/news/in-paris/articles/212134-coronavirus-in-the-world-as-of-friday-february-19-2021-latest-case-and-death-tol/lang/en.
Williams, T. C., & Burgers, W. A. (2021). SARS-CoV-2 evolution and vaccines: cause for concern? The Lancet Respiratory Medicine.
Corum, J., Grady, D., Wee, S. L., & Zimmer, C. (2020). Coronavirus vaccine tracker. The New York Times, 5.
COVID-19 Vaccines. (2020). https://emedicine.medscape.com. Retrieved from: https://emedicine.medscape.com/article/2500139-overview?src=
Komisarenko, S.V. (2020). Scientist’s pursuit for coronavirus SARS-COV-2, which causes COVID-19: scientific strategies against pandemic. Visn. Nats. Akad. Nauk Ukr., 8, 29-37 [in Urkainian].
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., ... & Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 369(6499), 77-81.
Mueller, S., Stauft, C. B., Kalkeri, R., Koidei, F., Kushnir, A., Tasker, S., & Coleman, J. R. (2020). A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine, 38(14), 2943-2948.
Funk, C. D., Laferrière, C., & Ardakani, A. (2020). A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Frontiers in Pharmacology, 11, 937.
Comirnaty. (2020). https://www.ema.europa.eu. Retrieved from: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty.
Pfizer and Biontech propose expansion of pivotal COVID-19 vaccine trial. (2020). https://www.businesswire.com. Retrieved from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19
Pfizer and Biontech propose expansion of pivotal COVID-19 vaccine trial. (2020). https://www.nytimes.com. Retrieved from: https://www.nytimes.com/interactive/2020/health/pfizer-biontech-covid-19-vaccine.html.
Walsh, E.E., Frenck Jr,R.W., Falsey, A.R., Kitchin, N., Absalon, J., Gurtman, A., ... & Gruber, W.C. (2020). Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine, 383 (25), 2439-2450.
Diseases, T. L. I. (2021). An exceptional vaccination policy in exceptional circumstances. The Lancet. Infectious Diseases, 21 (2), 149.
Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines. (2020). https://www.gov.uk. Retrieved from: https://www.gov.uk/government/news/statement-from-the-uk-chief-medical-officers-on-the-prioritisation-of-first-doses-of-covid-19-vaccines.
Optimising the COVID-19 vaccination programme for maximum short-term impact. (2020). https://www.gov.uk. Retrieved from: https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact
How Moderna`s vaccine works. (2020). https://www.nytimes.com. Retrieved from: https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html.
Haynes, B. F. (2020). A New Vaccine to Battle Covid-19. The New England journal of medicine.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Gruber, W.C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383 (27), 2603-2615.
The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. (2020). https://www.who.int. Retrieved from: https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know.
Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... & Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384 (5), 403-416.
Widge, A.T., Rouphael, N.G., Jackson, L.A., Anderson, E.J., Roberts, P.C., Makhene, M., ... & Beigel, J.H. (2021). Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. New England Journal of Medicine, 384 (1), 80-82.
Graham, B.S. (2020). Rapid COVID-19 vaccine development. Science, 368 (6494), 945-946.
Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J., & Haynes, B. F. (2020). Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell.
Moderna. Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. (2020). https://investors.modernatx.com. Retrieved from: https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
Dey, A., Rajanathan, C., Chandra, H., Pericherla, H.P., Kumar, S., Choonia, H.S., ... & Maithal, K. (2021). Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models. bioRxiv.
ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models. (2021). https://www.news-medical.net. Retrieved from: https://www.news-medical.net/news/20210202/ZyCoV-D-DNA-vaccine-immunogenic-against-SARS-CoV-2-in-animal-models.aspx.
What is a DNA-based vaccine? (2021). https://www.news-medical.net. Retrieved from: https://www.news-medical.net/health/What-is-a-DNA-based-vaccine.aspx.
What are Spike Proteins? (2021). https://www.news-medical.net. Retrieved from: https://www.news-medical.net/health/What-are-Spike-Proteins.aspx.
Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., ... & Bijker, E. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397 (10269), 99-111.
Knoll, M.D., & Wonodi, C. (2021). Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet, 397 (10269), 72-74.
Oxford University to test COVID-19 vaccine response among children for first time. (2021). https://www.reuters.com. Retrieved from: https://www.reuters.com/article/idUSKBN2AD07S.
Viruses sampling products – viruses collection. (2020). https://www.nytimes.com. Retrieved from: https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html.
The AstraZeneca Covid vaccine data isn’t up to snuff. (2020). https://www.wired.com. Retrieved from: https://www.wired.com/story/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff/amp.
Corum, J., Grady, D., Wee, S.L., & Zimmer, C. (2020). Coronavirus vaccine tracker. The New York Times, 5.
Center for Systems Science and Engineering at Johns Hopkins University COVID-19 dashboard. Johns Hopkins University of Medicine coronavirus resource center. (2020). Retrieved from: https://coronavirus.jhu.edu. Retrieved from: https://coronavirus.jhu.edu/map.html.
Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., ... & Bijker, E. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397 (10269), 99-111.
Ramasamy, M.N., Minassian, A.M., Ewer, K.J., Flaxman, A.L., Folegatti, P.M., Owens, D.R., ... & Demissie, T. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396 (10267), 1979-1993.
Adenovirus-vectored Covid-19 vaccines’ efficacy during a potential revaccination campaign likely to be stifled by antivector response. (2021). https://www.clinicaltrialsarena.com. Retrieved from: https://www.clinicaltrialsarena.com/comment/adenovirus-vectored-covid-19-vaccines-efficacy-during-a-potential-revaccination/.
AstraZeneca to test if combination of its Covid vaccine with Russia’s Sputnik V works better. (2021). https://theprint.in. Retrieved from: https://theprint.in/health/astrazeneca-to-test-if-combination-of-its-covid-vaccine-with-russias-sputnik-v-works-better/565146/.
Callaway, E. (2020). Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature, 584 (7821), 334-335.
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., ... & Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26. COV2. S Covid-19 Vaccine. New England Journal of Medicine.
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. (2020). https://www.jnj.com. Retrieved from: https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial.
A Randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older. (2020). https://www.jnj.com. Retrieved from: https://www.jnj.com/coronavirus/ensemble-1-study-protocol.
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. (2021). https://ir.novavax.com. Retrieved from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3.
How the Novavax vaccine works. (2021). https://www.nytimes.com. Retrieved from: https://www.nytimes.com/interactive/2020/health/novavax-covid-19-vaccine.html.
Clinical trials. (2020). https://www.clinicaltrialsregister.eu. Retrieved from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB.
China’s Sinopharm vaccine has 86% efficacy against Covid-19, says UAE. (2020). https://edition.cnn.com. Retrieved from: https://edition.cnn.com/2020/12/09/asia/uae-china-vaccine-intl-hnk/index.html.
Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., ... & Yang, X. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases, 21 (1), 39-51.
How the Sinopharm Vaccine Works. (2021). https://www.nytimes.com. Retrieved from: https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html.
Sinopharm COVID-19 vaccine could be cleared for use in minors before March: state media. (2021). https://www.reuters.com. Retrieved from: https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN29K0SE.
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., ... & Zhu, F. (2020). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases.
Exclusive: FDA widens U.S. safety inquiry into AstraZeneca coronavirus vaccine – sources. (2020). https://www.reuters.com. Retrieved from: https://www.reuters.com/article/us-health-coronavirus-vaccine-astrazenec-idUSKBN26L3TA.
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... & Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384 (5), 403-416.
Widge, A.T., Rouphael, N.G., Jackson, L.A., Anderson, E.J., Roberts, P.C., Makhene, M., ... & Beigel, J.H. (2021). Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. New England Journal of Medicine, 384 (1), 80-82.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506.
Liu, Y., Mao, B., Liang, S., Yang, J.W., Lu, H.W., Chai, Y.H., ... & Xu, J.F. (2020). Association between age and clinical characteristics and outcomes of COVID-19. European Respiratory Journal, 55 (5).
Shahid, Z., Kalayanamitra, R., McClafferty, B., Kepko, D., Ramgobin, D., Patel, R., ... & Jain, R. (2020). COVID‐19 and older adults: what we know. Journal of the American Geriatrics Society, 68 (5), 926-929.
Saadat, S., Rikhtegaran-Tehrani, Z., Logue, J., Newman, M., Frieman, M. B., Harris, A. D., & Sajadi, M.M. (2021). Single dose vaccination in healthcare workers previously infected with SARS-CoV-2. MedRxiv.
Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., ... & Crotty, S. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science.
Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N., ... & Beigel, J.H. (2020). An mRNA vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine.
WHO Recommends Most Pregnant Women Don’t Use Moderna, Pfizer Vaccines. (2021). https://www.wsj.com. Retrieved from: https://www.wsj.com/livecoverage/covid-2021-01-27/card/lVPw3ARYl1DlbFZbzKBZ.
WHO: Mass vaccination will not eradicate the coronavirus. (2021). https://www.dw.com/uk. Retrieved from: https://www.dw.com/uk/vooz-masova-vaktsynatsiia-ne-pryzvede-do-vykorinennia-koronavirusu/a-55757137 [in Ukrainian].
AP-NORC poll: Only half in US want shots as vaccine nears. – 2020. – https://apnews.com. Electronic resource. Retrieved from: https://apnews.com/article/ap-norc-poll-us-half-want-vaccine-shots-4d98dbfc0a64d60d52ac84c3065dac55.
Dodd, R. H., Pickles, K., Nickel, B., Cvejic, E., Ayre, J., Batcup, C., ... & McCaffery, K.J. (2021). Concerns and motivations about COVID-19 vaccination. The Lancet. Infectious Diseases, 21(2), 161.
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. New England Journal of Medicine, 382 (21), 1969-1973.
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2021 Інфекційні хвороби
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
- Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
